Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
clinical improvementclinical worseningdeathsPCR-negative conversion
chloroquine and derivatives3- OBS 0.93 [0.48; 1.81], 1 study, I2=0%
inconclusive result
0.99 [0.51; 1.91], 1 RCT, I2=0%
inconclusive result
-
azithromycin1- 1.36 [0.94; 1.97], 1 RCT, I2=0%
inconclusive result
1.08 [0.79; 1.47], 1 RCT, I2=0%
inconclusive result
-
remdesevir1 1.23 [0.87; 1.74], 1 RCT, I2=0%
inconclusive result
- 1.10 [0.49; 2.45], 1 RCT, I2=0%
inconclusive result
-
ASC09/ritonavir0----
azvudine0----
baloxavir marboxil0----
bromhexine0----
carrimycin0----
danoprevir / ritonavir0----
darunavir cobicistat0----
darunavir/cobicistat plus chloroquine0----
favipiravir 0----
fluvoxamine0----
hydroxychloroquine plus macrolides0----
interferon0----
ivermectin0----
leronlimab0----
lopinavir / ritonavir plus ribavirin0----
lopinavir/ritonavir0----
lopinavir/ritonavir plus chloroquine0----
lopinavir/ritonavir plus interferon ß-1a0----
lopinavir/ritonavir, ribavirin and interferon beta-1b0----
meplazumab0----
nitazoxanide0----
oseltamivir0----
oseltamivir plus chloroquin0----
Renin-angiotensin-system-acting agents0----
ribavirin0----
ritonavir0----
tenofovir/emtricitabine0----
tenofovir/emtricitabine plus hydroxychloroquine0----
tranexamic acid0----
triazavirin0----
umifenovir (arbidol)0----